Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
62 studies found for:    "Kidney Neoplasms" AND (woman OR women OR female)
Show Display Options
Rank Status Study
21 Completed Acceptability of Less Harmful Alternatives to Cigarettes
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Behavioral: telephone-based intervention;   Drug: nicotine replacement therapy;   Other: informational intervention;   Other: internet-based intervention;   Other: questionnaire administration
22 Completed
Has Results
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Drug: nicotine;   Drug: varenicline;   Other: placebo
23 Completed Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Behavioral: smoking cessation intervention;   Drug: bupropion hydrochloride;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Other: counseling intervention;   Other: educational intervention;   Procedure: psychosocial assessment and care
24 Completed Bupropion in Helping Adults Stop Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Drug: bupropion hydrochloride;   Other: placebo
25 Completed Zinc Supplements in Lowering Cadmium Levels in Smokers
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Intervention: Dietary Supplement: zinc oxide
26 Completed
Has Results
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Conditions: Bladder Cancer;   Cervical Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Kidney Cancer;   Leukemia;   Liver Cancer;   Lung Cancer;   Pancreatic Cancer;   Tobacco Use Disorder
Interventions: Drug: nicotine lozenge;   Drug: nicotine patch
27 Active, not recruiting Pillars4Life Trial
Conditions: Breast Cancer;   Lung Cancer;   Esophageal Cancer;   Colon Cancer;   Pancreatic Cancer;   Liver Cancer;   Renal Cancer;   Bladder Cancer;   Prostate Cancer;   Ovarian Cancer;   Cervical Cancer;   Uterine Cancer
Intervention: Behavioral: Pillars4Life
28 Recruiting Prospective Analysis of Robot-Assisted Surgery
Conditions: Esophageal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Rectal Cancer;   Bladder Cancer;   Prostate Cancer;   Renal Cancer;   Uterus Cancer;   Head and Neck Cancer;   Lung Cancer
Interventions: Procedure: Robot-assisted surgery;   Procedure: Conventional Surgery
29 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis, High Risk Individuals, and Individuals With No History of Cancer (Control)
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
Intervention:
30 Recruiting A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Selected Tumors With Rhabdoid Features;   Synovial Sarcoma;   INI1-negative Tumors;   Malignant Rhabdoid Tumor of Ovary;   Renal Medullary Carcinoma;   Epithelioid Sarcoma
Intervention: Drug: Tazemetostat
31 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
32 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
33 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
34 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
35 Recruiting Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
Condition: Vertebral Metastasis
Intervention: Radiation: Conformal High Dose Intensity Modulated Radiation Therapy
36 Withdrawn A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Conditions: Colon Cancer;   Lung Cancer;   Cervical Cancer;   Renal Cell Carcinoma;   Uterine Cancer
Intervention: Drug: (18)Fluciclatide
37 Recruiting Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Conditions: Pleuropulmonary Blastoma;   Cystic Nephroma;   Sertoli-Leydig Cell Tumor of Ovary;   Medulloepithelioma;   Embryonal Rhabdomyosarcoma of Cervix;   Goiter;   Sarcoma;   Pineoblastoma;   Pituitary Tumors;   Wilms Tumor
Intervention:
38 Completed Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Conditions: Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Endometrial Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: temsirolimus;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
39 Completed
Has Results
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Conditions: Cutaneous Leiomyomas;   Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions: Biological: Botulinum toxin type A;   Other: Placebo
40 Not yet recruiting HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Conditions: Epithelial Ovarian Cancer;   Renal Cell Carcinoma
Intervention: Drug: HKT288

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.